Loading…
Loading…
CHB (Global X China Biotech Innovation ETF) is no longer actively trading.
This usually means the fund has been liquidated, merged into another product, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference, not a current-day signal.
The fund invests at least 80% of its total assets, plus borrowings for investments purposes (if any), in the securities of the underlying index and in American Depositary Receipts ("ADRs") and Global Depositary Receipts ("GDRs") based on the securities in the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are directly involved in China’s biotechnology industry. It is non-diversified.
Is CHB's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
[url="]Ionis Pharmaceuticals, Inc.[/url] (Nasdaq: IONS) partner GSK today announced that the U.S. Food and Drug Administration (FDA) has approved Hibsago(bepiro
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced that the U.S. Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B (CHB) virus infection in combination with nucleos(t)ide analogue reverse transcriptase inhibitor (NrtI) therapy in adult patients without cirrhosis, receiving NrtI therapy for at least 6 months, who have suppressed HBV deoxyribonucleic acid (DNA), and with hepatitis.
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B (CHB) virus infection in combination with nucleos(t)ide analogue reverse transcriptase inhibitor (NrtI) therapy in adult patients without cirrhosis, receiving NrtI therapy for at least 6 months, who have suppressed HBV deoxyribonucleic acid (DNA), and with hepatitis B virus (HBV) surface antigen (HBsAg).
[url="]Ionis Pharmaceuticals, Inc.[/url] (Nasdaq: IONS) partner GSK today announced positive pivotal data for bepirovirsen, an investigational antisense oligon
Targeting New JORC Mineral Resources at 'Challenger 3' Target HIGHLIGHTS 8,065m reverse circulation (RC) Resource upgrade drilling recently completed at Challenger ‘Main', ‘Challenger West' (CW) open pits, and ‘Challenger South-Southwest' (CSSW) and ‘Challenger 3' targets1 New assays confirm CSSW and Challenger 3 mineralisation, and support a potential new Challenger 3 JORC (2012) Mineral Resource Estimate (MRE), including: Hole ID Interval Including: CHB0197 8m @ 1.68 g/t Au from 55 metres 1m @ 7.64 g/t Au from 57 metres CHB0204 6m @ 4.46 g/t Au from 30 metres 2m @ 12.1 g/t Au from 30 metres CHB0206 10m @ 1.33 g/t Au from 44 metres 1m @ 5.61 g/t Au from 46 metres CHB0213 10m @ 2.28 g/t Au from 33 metres 1m @ 9.12 g/t Au from 42 metres CHB0222 7m @ 3.28 g/t Au from 30 metres 1m @ 16.5 g/t Au from 30 metres CHB0225 2m @ 5.12 g/t Au from 30 metres 1m @ 9.17g/t Au from 31 metres CHB0236 6m @ 1.66 g/t Au from 24 metres 1m @ 6.93 g/t Au from 25 metres Recent assays have also identified new high-grade mineralisation up to 170 g/t Au in the ‘Main' open pit walls, and mineralisation up to 60 g/t Au in the Challenger West open pit floor2 Challenger DFS underway targeting a viable, simplified ‘baseline' Stage 1 operation to underwrite restart of CGM and maximise Challenger, Tarcoola, Wudinna and Tolmer development optionality ADELAIDE, AU / ACCESS Newswire / May 19, 2026 / Barton Gold Holdings Limited (ASX:BGD)(OTCQB:BGDFF)(FRA:BGD3) (Barton or Company) is pleased to announce further assay results from recent drilling at its South Australian Challenger Gold Project (Challenger). These assays come from the CSSW Deposit and ‘Challenger 3' target, both of which are potential new open pits.